Open Access
Issue
SHS Web Conf.
Volume 144, 2022
2022 International Conference on Science and Technology Ethics and Human Future (STEHF 2022)
Article Number 01013
Number of page(s) 4
Section Research on Bioethics and Medical Science and Technology Ethics
DOI https://doi.org/10.1051/shsconf/202214401013
Published online 26 August 2022
  1. Suresh J., Khor I. W., Kaur P., et al. Shared signaling path⁃ ways in Alzheimer’s and metabolic disease may point to new treatment approaches [J]. FEBS J, 2020. [Google Scholar]
  2. Blennow K, De Leon M. J., Zetterberg H. Alzheimer’s disease [J]. Lancet, 2006, 368(9533): 387-403. [CrossRef] [Google Scholar]
  3. Astroski J. W., Akporyoe L. K., Androphy E. J., et al. Mutations in the COPI coatomer subunit α-COP induce release of Aβ-42 and amyloid precursor protein intracellular domain and increase tau oligomerization and release [J] Neurobiol Aging, 2021, 13(1): 57. [CrossRef] [Google Scholar]
  4. Wang X., Wang W., LI L., et al. Oxidative stress and mitochondrial dysfunction in Alzheimer’s disease [J]. Biochim Biophys Acta, 2014, 1842(8):1240-1247. [CrossRef] [Google Scholar]
  5. Ossenkoppele R., Schonhaut D. R., Schöll M., et al. Tau PET patterns mirror clinical and neuroanatomical variability in Alzheimer’s disease [J] Brain, 2016, 139(5): 1551-1567. [CrossRef] [Google Scholar]
  6. Egan M. F., Kost J., Tariot PN, et al. Randomized trial of verubecestat for mild-to-moderate Alzheimer’s disease [J] N Engl J. Med, 2018, 378(18):1691-1703. [CrossRef] [Google Scholar]
  7. Justin M. L, David M. H. Alzheimer disease: an update on pathobiology and treatment strategies [J] Cell, 2019(2), pp.312-339. [Google Scholar]
  8. Zhang Lei, Fan Zhanfang, Zhang Zuopeng, Cheng Mousheng, Liu Yang. Research progress on the pathogenesis of Alzheimer’s disease and related therapeutic drugs [J]. Chinese Journal of Medicinal Chemistry, 2021, 31(06):438-446+469. [Google Scholar]
  9. Burstein A. H., Grimes I., Galasko D R, et al. Effect of TTP488 in patients with mild to moderate Alzheimer’s disease [J] BMC Neurol, 2014. [Google Scholar]
  10. Huang, S. J. FDA grants drug status to LMTX, a rare disease treatment for frontotemporal dementia [J]. International Journal of Pharmaceutical Research, 2019. [Google Scholar]
  11. Wang Xiaohua. Application of affectionate care combined with psychological care in the treatment of patients with Alzheimer’s disease [J] Integrated Chinese and Western Medicine Nursing (in Chinese and English), 2020, 6(11):72-75. [Google Scholar]
  12. Porrini V, Lanzillotta A, Branca C, et al. CHF5074 (CSP-1103) induces microglia alternative activation in plaque-free Tg2576 mice and primary glial cultures exposed to beta-amyloid [J]. Neuroscience, 2015, 302: 112-120. [CrossRef] [Google Scholar]
  13. Merlini M, Kirabali T, Luka K, et al. Extravascular CD3 + T cells in brains of Alzheimer disease patients correlate with tau but not with amy-loid pathology: an immunohistochemical study [J]. Neurodegener Dis, 2018, 18(1): 49-56. [CrossRef] [Google Scholar]
  14. Xiaohua Wang. Application of affectionate care combined with psychological care in the treatment of patients with Alzheimer’s disease [J] Integrated Chinese and Western Medicine Nursing, 2020, 6(11):72-75. [Google Scholar]

Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.

Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.

Initial download of the metrics may take a while.